The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study.

[1]  M. Brady,et al.  Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience , 2010, Cancer.

[2]  L. Ries,et al.  Ovarian cancer: Survival and treatment differences by age , 2010, Cancer.

[3]  A. Sood,et al.  Docetaxel Versus Paclitaxel for Adjuvant Treatment of Ovarian Cancer: Case–Control Analysis of Toxicity , 2004, American journal of clinical oncology.

[4]  P. Disaia,et al.  Stages III and IV Invasive Epithelial Ovarian Carcinoma in Younger Versus Older Women: What Prognostic Factors Are Important? , 2003, Obstetrics and gynecology.

[5]  A. Zaslavsky,et al.  Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. DiSilvestro,et al.  Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. , 2002, Gynecologic oncology.

[7]  A. Fishman,et al.  Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. , 2002, Gynecologic oncology.

[8]  R. Ozols.  Update on the management of ovarian cancer. , 2002, Cancer journal.

[9]  H. Hansen,et al.  Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma , 2002, Cancer.

[10]  J. Piccirillo,et al.  Importance of Comorbidity in Head and Neck Cancer , 2000, The Laryngoscope.

[11]  Yuchiao Chang,et al.  Epithelial ovarian carcinoma in the reproductive age group , 1999, Cancer.

[12]  J. Shepherd,et al.  FIGO staging of gynecologic cancer , 1999 .

[13]  J. Donnez.  Today's treatments: medical, surgical and in partnership , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  D. Kerr,et al.  Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. , 1998, European journal of cancer.

[15]  G. Lyman,et al.  Comorbidity and functional status are independent in older cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Havlik,et al.  The national institute on aging and the national cancer institute seer collaborative study on comorbidity and early diagnosis of cancer in the elderly , 1994, Cancer.

[17]  R. Barakat,et al.  Impact of age on survival of patients with ovarian cancer. , 1993, Gynecologic oncology.

[18]  J. Coebergh,et al.  Trends of Cancer in the Netherlands 1989-1998 , 2002 .

[19]  N. Petrelli,et al.  Age and sex are independent predictors of 5‐fluorouracil toxicity. Analysis of a large scale phase III trial , 1995, Cancer.

[20]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.